AxoGen (NASDAQ: AXGN) is one of 46 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its competitors? We will compare AxoGen to similar companies based on the strength of its dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.
Valuation & Earnings
This table compares AxoGen and its competitors gross revenue, earnings per share (EPS) and valuation.
AxoGen’s competitors have higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares AxoGen and its competitors’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Insider and Institutional Ownership
67.8% of AxoGen shares are held by institutional investors. Comparatively, 41.9% of shares of all “Electromedical equipment” companies are held by institutional investors. 7.9% of AxoGen shares are held by insiders. Comparatively, 20.6% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
AxoGen has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, AxoGen’s competitors have a beta of 1.58, suggesting that their average stock price is 58% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for AxoGen and its competitors, as reported by MarketBeat.com.
||Strong Buy Ratings
AxoGen presently has a consensus price target of $33.14, indicating a potential downside of 17.86%. As a group, “Electromedical equipment” companies have a potential upside of 20.76%. Given AxoGen’s competitors higher probable upside, analysts clearly believe AxoGen has less favorable growth aspects than its competitors.
AxoGen competitors beat AxoGen on 9 of the 13 factors compared.
AxoGen Company Profile
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.